34 research outputs found
Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
Get PDF
Effective behaviour change techniques for physical activity and healthy eating in overweight and obese adults; systematic review and meta-regression analyses
Full text linkResponse to Letter: "Radiation Is Not a Solution for Suboptimal Surgery. A Response to the Conclusions Drawn From the Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma With or Without Neoadjuvant Chemoradiotherapy Study''
No full textUpdated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer
No full textClinical Complete Response After Neoadjuvant Therapy for Esophageal Cancer: What’s Lurking Under the Surface?
No full textDevelopment of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports
Get PDFIntraperitoneal chemotherapy for peritoneal metastases of gastric origin:A systematic review and meta-analysis
No full textBackground:Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Catheter-based intraperitoneal (IP) chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs, compared to intravenous administration. We reviewed the effectiveness of palliative intraperitoneal chemotherapy for patients with peritoneal metastases of gastric origin.Methods:Embase, MEDLINE, Web of Science, and Cochrane were searched for articles on chemotherapy with palliative intent in patients with peritoneal metastases of gastric origin published up to April 2023. The primary outcome was overall survival. Secondary outcomes included toxicity and clinicopathological outcomes in patients that underwent conversion surgery. A Bayesian random effect model was used to calculate the pooled median overall survival (mOS).Results:21 studies including 904 patients were retrieved, categorized in 3 treatment groups (IP docetaxel, IP paclitaxel and PIPAC). The pooled mOS for all intraperitoneal chemotherapy treatments was 14.2 months (95% CI: 10.8 – 17.7 months). The pooled hazard ratio of IP paclitaxel and docetaxel favored the combination of IP and systemic chemotherapy compared to systemic chemotherapy only (0.64, 95% CI: 0.47 – 0.86). mOS of IP paclitaxel, IP docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.3 months (95% CI: 14.0 – 22.7 months), 13.2 months (95% CI: 3.6 – 25.1 months) and 9.0 months (95% CI: 2.3 – 16.5 months). All treatment methods had a relatively safe toxicity profile. Conversion surgery was performed in 14% of the patients and a radical resection was achieved in 69%, with a mOS ranging from 24 to 33 months.Conclusions:Patients with peritoneal metastases of gastric origin treated with intraperitoneal chemotherapy had a pooled median overall survival of 14.2 months and a pooled hazard ratio of 0.64 compared to systemic chemotherapy. Intraperitoneal chemotherapy, regardless of method of administration, is a safe treatment and conversion surgery is possible in a selected subset of patients
Intraperitoneal chemotherapy for peritoneal metastases of gastric origin:A systematic review and meta-analysis
No full textBackground:Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Catheter-based intraperitoneal (IP) chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs, compared to intravenous administration. We reviewed the effectiveness of palliative intraperitoneal chemotherapy for patients with peritoneal metastases of gastric origin.Methods:Embase, MEDLINE, Web of Science, and Cochrane were searched for articles on chemotherapy with palliative intent in patients with peritoneal metastases of gastric origin published up to April 2023. The primary outcome was overall survival. Secondary outcomes included toxicity and clinicopathological outcomes in patients that underwent conversion surgery. A Bayesian random effect model was used to calculate the pooled median overall survival (mOS).Results:21 studies including 904 patients were retrieved, categorized in 3 treatment groups (IP docetaxel, IP paclitaxel and PIPAC). The pooled mOS for all intraperitoneal chemotherapy treatments was 14.2 months (95% CI: 10.8 – 17.7 months). The pooled hazard ratio of IP paclitaxel and docetaxel favored the combination of IP and systemic chemotherapy compared to systemic chemotherapy only (0.64, 95% CI: 0.47 – 0.86). mOS of IP paclitaxel, IP docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.3 months (95% CI: 14.0 – 22.7 months), 13.2 months (95% CI: 3.6 – 25.1 months) and 9.0 months (95% CI: 2.3 – 16.5 months). All treatment methods had a relatively safe toxicity profile. Conversion surgery was performed in 14% of the patients and a radical resection was achieved in 69%, with a mOS ranging from 24 to 33 months.Conclusions:Patients with peritoneal metastases of gastric origin treated with intraperitoneal chemotherapy had a pooled median overall survival of 14.2 months and a pooled hazard ratio of 0.64 compared to systemic chemotherapy. Intraperitoneal chemotherapy, regardless of method of administration, is a safe treatment and conversion surgery is possible in a selected subset of patients
Salvage Esophagectomy for Residual Tumor After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Invading the Neighboring Organs: Is it a Feasible Choice?
No full text
